Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1376 - 1400 of 1804 in total

Sarilumab

Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL ... in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid ... human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Biologics for Rheumatoid Arthritis Treatment …
Matched Products: … KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG ... KEVZARA Solution for Injection in Pre-filled Pen 150mg ... KEVZARA Solution for Injection in Pre-filled Pen 200mg …

Luspatercept

Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and ... in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic ... [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Intracellular Signaling Peptides and Proteins …
Matched Products: … Reblozyl 25 mg powder for solution for injection ... Reblozyl 75 mg powder for solution for injection …

Styphnolobium japonicum flower bud

Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Products: … BARAMO for O ily Scalp ... BARAMO for Normal Scalp ... BARAMO Scalp Serum for Normal Scalp …

Panitumumab

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … Vectibix Concentrate for Solution for Infusion 100 mg/vial ... Vectibix 100mg Concentrate for Solution for Infusion …

Benralizumab

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R,...
Approved
Investigational
Matched Description: … , macrophages and neutrophils. ... global biologic research and development arm. ... specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Obstructive Airway Diseases …
Matched Products: … Fasenra 30 mg solution for injection in pre-filled syringe ... Fasenra 30mg Solution for Injection in Pre-filled Pen ... FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) …

Lixisenatide

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU. …
Matched Mixtures name: … LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide …
Matched Products: … LYXUMIA (SOLUTION FOR INJECTION 10 MCG) ... LYXUMIA (SOLUTION FOR INJECTION 20 MCG) ... Lyxumia 20mcg Solution for Injection …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10ML ... BAVENCIO 200 mg/10mL concentrate for solution for infusion …

Eravacycline

Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic...
Approved
Investigational
Matched Description: … tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and ... carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683]. ... to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIAL …

Cimicoxib

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
Matched Products: … Cimalgex 30mg chewable tablets for dogs ... Cimalgex 80mg chewable tablets for dogs ... Cimalgex 8mg chewable tablets for dogs …

Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy...
Approved
Investigational
Matched Description: … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older ... part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and ... It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Ilaris Powder for Solution for Injection 150mg/vial ... ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION …

Interferon beta-1a

Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Matched Products: … Rebif 22mcg/0.5ml solution for injection ... Rebif 44mcg/0.5ml solution for injection ... Rebif Solution for Injection in Cartridge 22mcg/0.5ml …

Etelcalcetide

Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Approved
Investigational
Matched Description: … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism ( ... Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Sex Hormones and Insulins ... Calcium Homeostasis ... Calcium-sensing Receptor Agonist ... Increased Calcium-sensing Receptor Sensitivity …
Matched Products: … PARSABIV SOLUTION FOR INJECTION 5 mg/mL ... Parsabiv 5mg solution for injection ... PARSABIV SOLUTION FOR INJECTION 2.5 mg/0.5 mL …

Tigecycline

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil ... Food and Drug Administration (FDA) on June 17, 2005. …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion ... TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIAL ... TIGAR 50 (Tigecycline Powder for Solution for Infusion 50mg/Vial) …

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically...
Approved
Investigational
Matched Description: … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who ... By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and ... with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …

Inotuzumab ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for ... fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Drugs for Treatment of Bone Diseases …
Matched Products: … XGEVA 120mg Solution for Injection ... XGEVA Solution for Injection 120 mg/vial ... Prolia Solution for Injection 60mg Pre-filled Syringe …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... ] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …

Deferoxamine

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …

Decitabine

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.[A215082, A215092] Among treatment options, nucleoside analogues such as...
Approved
Investigational
Matched Description: … approved by the FDA for the treatment of MDS on February 5, 2006. ... presentation, including neutropenia and thrombocytopenia. ... and related downstream therapeutic benefits. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …

Daunorubicin

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Approved
Matched Description: … , used in treatment of leukemia and other neoplasms. ... A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... cytarabine and daunorubicin ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …

Avalglucosidase alfa

Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … , especially in smooth, cardiac, and skeletal muscle cells. ... In Pompe disease, the GAA enzyme is missing and patients are unable to properly break down glycogen, ... muscle weakness, which leads to premature death and debilitating effects on people’s lives. …
Matched Categories: … Alimentary Tract and Metabolism ... Enzymes and Coenzymes …
Matched Products: … NEXVIAZYME 100mg Powder for Concentrate for Solution for Infusion …

Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Matched Description: … Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant ... Atosiban is an inhibitor of the hormones oxytocin and vasopressin. ... Although initial studies suggested it could be used as a nasal spray and hence would not require hospital …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … TRACTOCILE 7.5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION ... TRACTOCILE (7.5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) ... TRACTOCILE 7.5MG/ML,SOLUTION FOR INJECTION …

Atracurium besylate

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved
Matched Description: … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for …
Matched Products: … Atracurium - (for Single Dose ) ... Atracurium Kabi 10mg/ml Solution for Injection USP ... ATRACURIUM LABATEC IV SOLUTION FOR INJECTION 10MG/ML …

Plerixafor

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune...
Approved
Investigational
Matched Description: … of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures. ... Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment ... [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … Mozobil 20 mg/ml solution for injection ... Mozobil Solution for Injection 20mg/ml ... PLERIXAFOR SEACROSS 20 MG/ML SOLUTION FOR INJECTION …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... Tremfya One-Press 100mg/ml Solution for Injection ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML …
Displaying drugs 1376 - 1400 of 1804 in total